HCA
ATRA icon

Harbor Capital Advisors’s Atara Biotherapeutics ATRA Stock Holding History

Harbor Capital Advisors’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-8,353
Closed -$107K – 755
2023
Q4 		$107K Buy
8,353
+6,568
+368% +$153K 0.02% 413
2023
Q3 		$66K Sell
1,785
-218
-11% -$9.7K 0.01% 428
2023
Q2 		$80.6K Buy
+2,003
New +$113K 0.02% 453

Other funds holding ATRA

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Harbor Capital Advisors's ATRA Position: Q1 2024 in Review

Harbor Capital Advisors sold out of Atara Biotherapeutics (ATRA) in Q1 2024, closing a stake of 8,353 shares — an estimated $107K sold.

Harbor Capital Advisors first reported a position in ATRA in Q2 2023 and held it in 3 quarters. The position peaked at $107K in Q4 2023. 82 funds tracked by Wall St. Rank hold ATRA as of Q1 2024.

  • Harbor Capital Advisors reported no remaining Atara Biotherapeutics position as of Q1 2024 after selling out during the quarter.
  • Harbor Capital Advisors sold 8,353 Atara Biotherapeutics shares in Q1 2024, an estimated $107K.
  • Harbor Capital Advisors first reported a position in Atara Biotherapeutics in Q2 2023 and held it in 3 quarters.
  • Harbor Capital Advisors's Atara Biotherapeutics position peaked at $107K in Q4 2023.
  • 82 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q1 2024.

Based on Harbor Capital Advisors's 13F filing for Q1 2024, filed 13 May 2024.